Dr Elena Galkina – Immune Control of Initiation and Progression of Atherosclerosis

Aug 2, 2019 | Biology, Health and Medicine

Atherosclerosis is a global health issue. Atherosclerosis is a multifactorial chronic inflammatory disease characterised by the accumulation of modified lipoproteins and immune cells in the aortic wall, vascular dysfunction, low-grade chronic inflammation, and formation of dangerous atherosclerotic plaques within the medium and large size vessels. Atherosclerosis is a prominent cause of cardiovascular diseases and mortality in many countries and this disease is closely associated with type 2 diabetes. Dr Elena Galkina, Professor of Microbiology and Molecular Cell Biology at Eastern Virginia Medical School, USA, has been working to determine the immune processes involved in an attempt to identify much-needed novel therapies.

The Immune Link with Atherosclerosis

A host of immune cell types have been associated with the initiation and progression of atherosclerosis. Dr Elena Galkina, Professor of Microbiology and Molecular Cell Biology at Eastern Virginia Medical School, USA, has identified the presence of many immune cell types, including both B- and T-lymphocytes, within normal aortic tissues as well as atherosclerotic tissue.

Furthermore, Dr Galkina has demonstrated that at least partial control of both T- and B-lymphocytes is managed by L-selectin, a molecule known to be involved in the ‘homing’ of T-cells to specific lymph nodes.

Function of B-lymphocytes in Atherosclerosis

Atherosclerosis, the leading cause of cardiovascular disease, accounted for approximately one-third of deaths in the USA in 2010. In an effort to reduce the rate of atherosclerosis development and progression, drugs or lifestyle changes are prescribed clinically. Unfortunately, this strategy only delivers an incomplete reduction of atherosclerosis.

Dr Galkina’s team indicate the imperative nature of further investigation into the pathways that may confer protection against initiation and progression of atherosclerosis. There is a substantial body of evidence that demonstrates the involvement of both the innate and adaptive immune response in the chronic inflammation that initiates and promotes atherosclerosis. Different cell types and even different sub-groups of the same cell type may be either pathological or protective with regards to atherosclerosis.

As the team has shown, B-cells are found in both atherosclerotic and normal aortic tissue, with differing ratios of B-lymphocytes of a specific sub-type being associated with atherosclerosis, both protective and disease-promoting.

It is largely accepted that B-cells do have a role in the initiation of atherosclerosis; however, the activation mechanism and the balance between protective versus disease promoting B-cell types remains to be elucidated.

Dr Elena Galkina and Colleagues

B-Cells and mLDL Uptake: Pathways and Cell Function Alterations

The research team is proposing to extend their work in the area of B-cell function and specific pathways for mLDL uptake, defining the pathways and, critically, the effect of this uptake on B-cell function. Initial research supports the induction of inhibitory pathways and changes in B-cell phenotype.

GRAIL and other E3 ligases are known to play a role in inducing tolerance in some immune cells, that is, they prevent the immune cell from responding to its own antigen target. Having demonstrated the presence of GRAIL and E3 ligases in B-cells, a collaborative team led by Dr Galkina and Dr Nurieva now proposes that a GRAIL-dependent mechanism is an inhibitory pathway that assists in regulating the B-cell activation threshold and induction of B-cells which do not respond to their antigen (anergic B-cells).

In their future plans, the team aims to identify the molecular mechanisms by which GRAIL exerts these effects on B-cells and the association with atherosclerosis.

Effector T-cells and Their Influence on Atherosclerosis Development

Dr Galkina and her colleagues have investigated the mechanism by which T-lymphocytes are involved in progressing atherosclerosis. Specifically, they interrogated the role of a receptor present on the surface of a sub-group of T-cells, CXCR6. They detected a significant correlation between this receptor expression on T-cells and atherosclerosis development.

In the absence of CXCR6, aortic lesion formation was found to be half that of CXCR6 sufficient mice. In addition, CXCR6 was positively associated with INF-γ, that is, where CXCR6 was low or absent, the concentration of pro-inflammatory cytokines was also reduced. Conversely, higher levels of CXCR6 induced production of INF-γ which, in turn, increased the recruitment of T-cells and macrophages (large white blood cells which are part of the immune system and a key component of atherogenesis) via up-regulation of a number of expressed proteins. Indeed, the team found that a population of CXCR6 deficient mice had a 90% reduction in one important sub-group of macrophages within the aorta.

Controlling Diabetes-associated Cardiovascular Disease

Cardiovascular disease related to atherosclerosis is increasing. Given the established link between inflammation of fat tissue, loss of beta cell function in the islets, and insulin resistance, the team of Dr Galkina and Dr Nadler team now intends to interrogate the link between loss of beta cell function and cardiovascular disease (CVD). They propose that identification of a shared pathway opens the door to developing dual-purpose therapies, that is, a methodology that addresses both beta cell decline and CVD.

Atherosclerosis is recognised as a major factor related to CVD in diabetic patients. As we have seen here, it is clear that atherosclerosis is a highly complex condition, involving a multitude of different pathways and systems throughout the body, and critically, includes the inflammatory immune response. Atherosclerosis-related inflammation is driven by a complex interaction and balance of immune cell subsets. However, within this myriad of immune cell interactions, there is a body of evidence that highlights the important role of myeloid cells in this damaging pathology.

Initiation of Atherosclerosis in Insulin Resistance

Investigating the link between atherosclerosis, obesity, insulin resistance, and type 2 diabetes, the research team of Dr Galkina and her EVMS collaborators Dr Nadler and Dr Dobrian established a link between STAT4, an immune regulatory factor, and increased inflammation in atherosclerosis and insulin resistance. Thereafter, Dr Galkina’s team focused their efforts on the effect of STAT4 on initiation of atherosclerosis, and specifically, the formation of plaques in cases of insulin resistance.

Using an animal model that displays both atherosclerosis and insulin resistance, the team found that low/no STAT4 levels leads to reduced atherosclerosis and enhances the metabolic response. Looking directly at the numbers of plaques in STAT4-deficient mice compared to diet-aligned controls, they found significantly fewer lesions – up to a 36% reduction. Furthermore, the plaque area at the aortic root was significantly smaller in the STAT4-deficient mice compared to controls.

The team extended the study timeline to account for the later stages of plaque formation and found that STAT4-deficient animals continued to show reduced plaque burden (at a rate of approximately 45% reduction) compared to matched controls.

Cellular Level Effects of STAT4 on Atherosclerosis Initiation

When the research team focused on the role of STAT4 with respect to immune cell infiltration and immune reactions, they found that the initiation of atherosclerosis was affected via pro-inflammatory macrophage activity, altering the ratio of two important sub-groups of T-lymphocytes, leading to local immune response modulation within the aortic cell wall in insulin resistance-accelerated atherosclerosis.

Importantly, these findings suggest a possible therapeutic role for the modulation of STAT4 expression in reducing the accelerated atherosclerosis that is associated with insulin resistance and type 2 diabetes.

In their future work, Dr Galkina’s and Dr Nadler’s research groups plan to untangle the pathways that drive myeloid cell activation and differentiation in atherosclerosis. They have previously investigated the important role of STAT4 in the mouse model, and they have demonstrated that deficiency – or blocking – of this important molecule conveys protection against atherosclerosis. They found that this occurs via control of macrophage activation and disruption of the delicate balance of cell recruitment, death, and proliferation. These areas of cellular activity are vital to the progress of their work.

The team will extend the reach of their work by investigating the role of STAT4 activation of neutrophils, which is known to lead to beta cell dysfunction, decreased metabolic activity, and increased atherosclerosis. The team hypothesises that there is a common pathway, linked to STAT4, which targets macrophages and neutrophils to progress the dual pathologies of type 2 diabetes and atherosclerosis. Importantly, this research will inform the development of innovative treatments to maintain beta cell mass and simultaneously reduce the accelerated cardiovascular disease which is strongly correlated with pre-diabetes and diabetes.

Diagram of Atherosclerosis: A Clogged Artery

Lymphocyte Populations and Pro-inflammatory Cytokines in Islet functions

It is well established that metabolic stress from excessive nutrition provokes islet inflammation and dysfunctions via lipotoxicity, and oxidative and endoplasmic reticulum stress, resulting in type 2 diabetes. While the role of the immune system in adipose tissue inflammation in type 2 diabetes is becoming more and more clear, very little is known about the impact of the immune system on islet health and functions in the conditions of type 2 diabetes. Thus, Dr Galkina and Dr Imai, an endocrinologist at the University of Iowa, initiated a project to determine lymphocyte and cytokine profiles in islets from normal human donors and type 2 diabetics. They found higher levels of CCL2, a protein that recruits specific immune cells to a site of inflammation, and TFN-α, an inflammatory cytokine, in type 2 diabetic derived islets when compared to normal islets.

In moderately functioning type 2 diabetic islets, some specific types of immune cells were increased in number when compared with poorly functioning islets. A range of both T- and B-lymphocytes was found in both healthy and damaged tissue; however, the team notes that the ratio of B-cells was significantly increased in the type 2 diabetic derived islets. The altered cell ratios point to a role of the adaptive immune response in islet damage. In terms of future plans, Dr Galkina and Dr Imai will focus their efforts on the characterisation of B lymphocyte functions in the regulation of islet dysfunction in pre-diabetic and type 2 diabetic patients.

Reference
https://doi.org/10.33548/SCIENTIA396

Meet the Team


Dr Elena V Galkina

Professor of Department of Microbiology and Molecular Cell Biology
Eastern Virginia Medical School
Norfolk, VA
USA

Dr Elena Galkina received her PhD in 1999 from the Saint-Petersburg Institute for Experimental Medicine, Russia. After completing a post-doctoral fellowship with the National Institute of Medical Research in the UK, she made the move to the University of Virginia, where she completed a postdoctoral fellowship before undertaking a series of academic position cumulating in her attainment of professorship in 2018. The focus of Dr Galkina’s research is the role of the immune system in cardiovascular disease, and in particular, on improving the understanding of immune cell involvement and efficacy of therapeutic agents with a view to reducing mortality. As a fellow of the American Heart Association, Dr Galkina is frequently invited to share her expertise at cardiovascular disease conferences and seminars, attended by international audiences.

CONTACT

E: galkinev@evms.edu

W: https://www.evms.edu/directory/profiles/elena-v-galkina.php

KEY COLLABORATORS

Dr Jerry Nadler, New York Medical College, Valhalla, USA

Dr Mark Kaplan, Indiana University, Indianapolis, USA

Dr Roza Nurieva, MD Anderson Cancer Center, University of Texas, Houston, USA

Dr Larry Sanford, Eastern Virginia Medical School, Norfolk, USA

Dr Yumi Imai, University of Iowa, Iowa City, USA

Dr John Cambier, University of Colorado, Boulder, USA

Dr Anca Dobrian, Eastern Virginia Medical School, Norfolk, USA

FUNDING

NIH National Heart, Lung, and Blood Institute (NHLBI R01 HL139000 and NHLBI R01 HL142129)

American Heart Association (AHA AIREA33960546)

FURTHER READING

E Galkina, A Kadl, J Sanders, D Varughese, I Sarembock, K Ley, Constitutive lymphocyte recruitment into the aortic wall prior to development of atherosclerosis is partially L-selectin-dependent, Journal of Experimental Medicine, 2006, 203, 1273–82.

E Galkina, B Harry, A Ludwig, E Liehn, C Weber, K Ley, CXCR6 promotes atherosclerosis by supporting T cell homing, interferon gamma production and macrophage accumulation in the aortic wall, Circulation, 2007, 116, 1801–11.

MJ Butcher, D Hallinger, E Garcia, Y Machida, S Chakrabarti, J Nadler, EV Galkina, Y Imai, Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes, Diabetologia, 2014, 57, 491–501.

P Taghavie-Moghadam, T Wassem, L Glenn, A Dobrian, M Kaplan, Y Yang, R Nurieva, J Nadler, E Galkina, STAT4 regulates CD8+Treg/Tfh cell axis and promotes atherogenesis in insulin-resistant Ldlr-/- mice, Journal of Immunology, 2017, 199, 3453–3465.

 

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

Subscribe now!


More articles you may like

Dr Robert Winglee – High Velocity Impacts: A New Way to Collect Samples from Space

For now, planetary scientists can only dream of getting their hands-on rock samples taken from the surfaces of distant worlds. Achieving these extractions presents a significant set of challenges, but Dr Robert Winglee and his colleagues at the University of Washington have made significant strides towards developing feasible techniques for retrieving samples. Through detailed computer design and field experiments, they have now clearly demonstrated that obtaining core samples created during high-velocity impacts with planetary surfaces could one day be a reality.

Dr Nicholas M. Teets – Advancing Genetic Control of Destructive Fruit Flies

Fruit flies cause significant annual damage to fruit crops globally by laying their eggs into healthy, living fruit tissue. The difficulty in predicting the attacks and controlling the flies before it is too late leads farmers to spray pesticides that can have damaging consequences for surrounding ecosystems. Dr Nicholas M. Teets and his team from the University of Kentucky’s Department of Entomology aim to eliminate the need for pesticides in the battle against these insect pests, through the development of sterile insects that are easy to rear and release en masse.

Dr Scott King – The Dawn Mission: Casting New Light on Ceres

The dwarf planet Ceres is just a fraction of the size of Pluto, yet it holds valuable information about the evolution of our solar system. As a member of the Dawn mission team, Dr Scott King at Virginia Tech has been using data gathered by NASA’s Dawn spacecraft to explore the interior structure of Ceres.

Dr Renée Arias | Dr Victor Sobolev | Dr Marshall Lamb – Ensuring Peanut Safety by Harnessing Plant Defences

Fungal toxins that may accumulate in peanuts pose a hidden threat to people globally. Whereas European countries and the USA have controls to prevent contaminated seed from entering the market, this is not available in many developing countries, where peanuts are a vital source of protein and nutrients. However, detecting and controlling these toxins has posed significant scientific and economic challenges. Dr Renée Arias, Dr Victor Sobolev and Dr Marshall Lamb of the USDA National Peanut Research Laboratory have pioneered methods for inhibiting toxin production using RNAi technology and enhancing natural peanut defences.